怀孕期间使用乙氨基和神经发育风险:生物学可信性
Delaine Pereira1, Anick Bérard2, Justine Pleau2
1Department of Biomedical and Molecular Sciences, and School of Environmental Studies, Queen's University, Kingston, ON.
概括
怀孕期间使用乙氨基并未明确与神经发育问题有关. 目前的证据有限,支持其谨慎使用,正如加拿大妇产科医生协会建议的那样.
科学领域:
- 围产期研究 围产期研究
- 神经发育毒理学 神经发育毒理学
- 在怀孕期间的药理学.
背景情况:
- 乙氨基 (偏醇) 是广泛用于疼痛和发烧在怀孕期间.
- 有关子宫内暴露后代的潜在神经发育影响存在担忧.
- 已经提出了机制性途径,但需要进一步研究.
研究的目的:
- 审查对乙氨基对胎儿神经发育的潜在影响的机制证据.
- 讨论当前动物和体外模型的局限性.
- 评估支持或反驳因果关系的证据的一致性.
主要方法:
- 对乙氨基和神经发育的机制研究 (动物,体外) 的审查.
- 考虑实验模型的局限性和人类相关性.
- 综合当前人类流行病学数据.
主要成果:
- 拟议的机械路径包括氧化应激,改变的传递体表达和表观遗传变化.
- 动物和体外模型在预测人类结果方面存在局限性.
- 现有的人类和机械学数据不足以确定典型剂量的因果关系.
结论:
- 目前的证据不支持在怀孕期间使用治疗性乙氨基和不良神经发育结果之间存在因果关系.
- 支持加拿大妇产科医生协会关于谨慎使用的建议.
- 需要进一步的高质量研究来澄清潜在的风险.
更多相关视频
05:13Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
575
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
11.7K
相关概念视频
Teratogenicity
3.9K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.9K
Factors Affecting Drug Response: Overview
2.8K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism
176
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Attention-Deficit/Hyperactivity Disorder
718
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
718
